Frequency of tumor-specific CD8⁺ T cells in paired blood and BM samples from 4 patients during the course of AZA administration. The percentage of frequency of CD8⁺CD137⁺ T cells responding to the peptide is shown. Values are calculated by subtracting the percentage detected in the unstimulated from the test.